Eye最新文献

Purpose: This prospective cohort study investigated the longitudinal relationship between hypertension (HTN), defined by the 2017 ACC/AHA guidelines, and changes in choroidal thickness (CT) in patients with type 2 diabetes.

Methods: Patients aged 30-80 years from the Guangzhou Diabetic Eye Study were categorized into non-HTN, stage 1-HTN, and stage 2-HTN groups based on BP criteria. Macular and parapapillary CT were measured using swept-source optical coherence tomography (SS-OCT). Mixed linear regression models analysed CT decline rates over a median 2.1-year follow-up, adjusting for confounders.

Results: 803 diabetes patients were included. Both stage 1-HTN and stage 2-HTN groups showed significantly thinner macular and parapapillary CT compared to non-HTN (all P < 0.05). Stage 2-HTN correlated with reduced macular CT thinning (coef = -11.29 μm/year; 95% CI, -22.36 to -0.22; P = 0.046) after adjustment, but not in the parapapillary area (coef = -4.07 μm/year; 95% CI, -12.89 to 4.74; P = 0.365). Subgroup analyses indicated faster macular CT decline in stage 2-HTN among those <65 years old (coef = -20.31 μm/year; 95% CI, -35.67 to -4.95; P = 0.10), males (coef = -14.1 μm/year; 95% CI, -32.54 to -4.33; P = 0.004), BMI ≥ 25 kg/m² (coef = -10.24 μm/year; 95% CI, -26.86 to -6.38; P = 0.007), HbA1c > 6.5% (coef = -8.91 μm/year; 95% CI, -13.49 to -4.68; P = 0.001), and diabetes duration <10 years (coef = -12.78 μm/year; 95% CI, -27.48 to -1.91; P = 0.008).

Conclusion: Stage 2-HTN is associated with accelerated macular CT loss in diabetic patients, suggesting macular CT measurements could potentially serve as early indicators of systemic hypertension. Further research is needed to establish precise CT cutoff values for clinical use in detecting and monitoring hypertension-related ocular changes.

Purpose: To determine the morphology and incidence of peripheral drusen-like deposits (DLDs) in eyes with pathological myopia (PM) using ultra-widefield (UWF) fundus photographs and UWF optical coherence tomographic (OCT) images.

Design: Retrospective, observational case series study.

Method: We reviewed the medical records of 676 patients (1352 eyes) with high myopia (HM) who were examined in the Advanced Clinical Centre for Myopia between 2017 and 2021. The main outcome measures were the incidence and morphological characteristics of the DLDs in the peripheral retina detected by ultra-widefield (UWF) imaging devices.

Results: Sixty-six of the 1352 (4.9%) eyes had peripheral DLDs. In 5 eyes, the DLDs were found at the staphyloma edge. The mean age of the patients was 70.0 ± 13.0 (range, 46.0-92.0) years, and the mean axial length was 29.8 ± 2.4 mm. Myopic macular neovascularization (MNV) was found in 41 of the 66 eyes with DLDs (62.1%). Patients with drusen in Zone 2 were significantly older than those in Zone 3 (80 ± 13 vs 64 ± 13 years; P < 0.001).

Conclusions: Ultra-widefield images showed that peripheral DLDs were present in 4.9% of highly myopic eyes. The findings in eyes with DLDs may provide a basis for the evaluations of the natural progression of peripheral retinal changes in eyes with PM.

Purpose: To investigate the effect of vitreomacular traction (VMT) on vitreous vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) levels in patients with active neovascular age-related macular degeneration (nAMD).

Design: A prospective, interventional, case-control study.

Methods: The study included a total of 70 patients from whom vitreous samples were obtained. The patients were categorized into four group: 10 patients with active nAMD accompanying VMT, 17 patients with VMT, 24 patients with active nAMD and 19 healthy patients without any diagnosis other than cataract. VEGF and PlGF levels were measured.

Results: The mean vitreous VEGF level was 34.7 ± 4.98 pg/ml in the nAMD and VMT group, 32.36 ± 4.55 pg/ml in the VMT group, 34.02 ± 3.79 pg/ml in the nAMD group, and 32.33 ± 2.4 pg/ml in the healthy control group. The mean vitreous PlGF level was 58.92 ± 20.83 pg/ml in the nAMD and VMT group, 46.29 ± 3.45 pg/ml in the VMT group, 54.64 ± 16.88 pg/ml in the nAMD group, and 53.66 ± 19.35 pg/ml in the healthy control group. No significant differences were observed in terms of vitreous VEGF and PlGF concentrations among the groups (p > 0.05 and p > 0.05, respectively). Aqueous humour VEGF and PlGF levels were significantly higher than vitreous levels in nAMD patients (p = 0.005 and p = 0.005, respectively).

Conclusion: The present study found no increases in vitreous VEGF and PlGF levels in both VMT + nAMD and VMT cases. Furthermore, patients with nAMD had significantly higher levels of PlGF and VEGF in aqueous humour compared to vitreous levels.

Background: To evaluate contrast sensitivity function (CSF) in convalescent Vogt-Koyanagi-Harada (VKH) disease and investigate the relationship between CSF and chorioretinal thickness in VKH patients with and without sunset glow fundus (SGF).

Methods: This is a cross-sectional study. Seventy-six eyes of VKH patients and 56 eyes of normal controls were evaluated. Patients were divided into SGF and non-SGF groups. The best-corrected visual acuity (BCVA) of all the participants was ≤0.0 logMAR. Their CSF and macular chorioretinal thickness were measured with quantitative CSF (qCSF) and Optical Coherence Tomography (OCT) and compared using repeated measures analysis of variance at the group level. Relationships between CSF and macular chorioretinal thickness were evaluated using generalized estimating equations.

Results: The CSF was significantly impaired in the SGF group compared to that in the control group (p = 0.001), especially at medium and high spatial frequencies. No significant CSF difference was found between the non-SGF group and control group, nor between the SGF and non-SGF groups. Compared to the controls, outer retinal thickness (ORT) in both VKH subgroups was significantly reduced (P < 0.001 or 0.005, respectively), although their outer nuclear layer thickness (ONLT) and choroidal thickness (CT) were not significantly different (both P = 1.000, P = 0.829 or 0.112, respectively). We found no significant correlation between CSF metrics and outer retinal thickness.

Conclusions: Despite good recovery of visual acuity, reduced CSF and outer retina thickness were found in convalescent VKH patients. CSF may be an important and sensitive metric to evaluate functional vision in VKH disease.

The transformative potential of genetic engineering in ophthalmology is remarkable, promising new treatments for a wide range of blinding eye diseases. The eye is an attractive target organ for genetic engineering approaches, in part due to its relatively immune-privileged status, its accessibility, and the ease of monitoring of efficacy and safety. Consequently, the eye has been at the forefront of genetic engineering advances in recent years. The development of Clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9), base editors, prime editors, and transposases have enabled efficient and specific gene modification. Ocular gene therapy continues to progress, with recent advances in delivery systems using viral / non-viral vectors and novel promoters and enhancers. New strategies to achieve neuroprotection and neuroregeneration are evolving, including direct in-vivo cell reprogramming and optogenetic approaches. In this review, we discuss recent advances in ocular genetic engineering, examine their current therapeutic roles, and explore their potential use in future strategies to reduce the growing burden of vision loss and blindness.